Related Experiment Video

Updated: Aug 11, 2026

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

Cardiac hypertrophy and hypertension

E Agabiti-Rosei1, M L Muiesan

  • 1Cattedra Semeiotica e Metodologia Medica, Università di Brescia, Italy. agabiti@master cci.unibs.it

Current Opinion in Nephrology and Hypertension
|April 8, 1998
PubMed

Insights

Left ventricular hypertrophy (LVH) predicts cardiovascular events in hypertension. Reversing LVH is a key therapeutic goal for hypertensive patients, potentially improving prognosis.

Area of Science:

  • Cardiology
  • Nephrology
  • Vascular Biology

Background:

  • Left ventricular hypertrophy (LVH) is a significant predictor of cardiovascular events in the general population and essential hypertension patients.
  • LVH prevalence rises with age and renal impairment severity, indicating its link to systemic health.
  • LVH serves as a sensitive marker for structural changes in both large and small arteries.

Purpose of the Study:

  • To review studies on left ventricular hypertrophy in the elderly.
  • To explore the relationship between cardiac and vascular hypertrophy.
  • To assess the potential for reversing LVH and its prognostic implications in hypertensive individuals.

Main Methods:

  • Review of existing studies on left ventricular hypertrophy.
  • Analysis of interrelations between cardiac and vascular structures.
  • Evaluation of prognostic value and reversibility of LVH.

Main Results:

  • Left ventricular hypertrophy is an independent predictor of cardiovascular events.
  • Age and renal impairment severity correlate with increased LVH prevalence.
  • LVH indicates vascular structural changes, highlighting its systemic impact.

Conclusions:

  • Reversing left ventricular hypertrophy is a critical therapeutic objective in managing hypertensive patients.
  • Understanding LVH characteristics, its reversibility, and prognostic value is essential for treatment strategies.
  • Further research into cardiac and vascular hypertrophy interrelations can inform therapeutic interventions.

More Related Videos

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats07:31

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats

Published on: December 2, 2016

Magnetic Adjustment of Afterload in Engineered Heart Tissues09:40

Magnetic Adjustment of Afterload in Engineered Heart Tissues

Published on: May 5, 2020

Related Concept Videos

Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
Mitral Regurgitation I: Introduction01:20

Mitral Regurgitation I: Introduction

Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cellular Adaptation II: Hypertrophy01:26

Cellular Adaptation II: Hypertrophy

Hypertrophy is the increase in the size of individual cells, resulting in the enlargement of a tissue or organ. Unlike hyperplasia, which involves an increase in cell number, hypertrophy is characterized by an increase in cell volume. This process often occurs in response to higher functional demand or hormonal stimulation, leading to the production of more structural proteins and organelles, thereby enhancing the cells' work capacity.There are two primary types of hypertrophy: physiological...